Avadel Pharmaceuticals (AVDL) Debt to Equity (2016 - 2022)
Historic Debt to Equity for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to -$10.95.
- Avadel Pharmaceuticals' Debt to Equity fell 86270.6% to -$10.95 in Q3 2022 from the same period last year, while for Sep 2022 it was -$10.95, marking a year-over-year decrease of 86270.6%. This contributed to the annual value of $1.82 for FY2021, which is 13033.26% up from last year.
- As of Q3 2022, Avadel Pharmaceuticals' Debt to Equity stood at -$10.95, which was down 86270.6% from -$40.31 recorded in Q2 2022.
- Avadel Pharmaceuticals' 5-year Debt to Equity high stood at $45.03 for Q4 2018, and its period low was -$40.31 during Q2 2022.
- Over the past 5 years, Avadel Pharmaceuticals' median Debt to Equity value was $0.74 (recorded in 2020), while the average stood at -$0.47.
- Per our database at Business Quant, Avadel Pharmaceuticals' Debt to Equity skyrocketed by 1124789.81% in 2021 and then plummeted by 348011.7% in 2022.
- Avadel Pharmaceuticals' Debt to Equity (Quarter) stood at $45.03 in 2018, then crashed by 109.68% to -$4.36 in 2019, then surged by 118.13% to $0.79 in 2020, then soared by 130.33% to $1.82 in 2021, then plummeted by 701.74% to -$10.95 in 2022.
- Its Debt to Equity stands at -$10.95 for Q3 2022, versus -$40.31 for Q2 2022 and $2.58 for Q1 2022.